KalVista Pharmaceuticals (KALV) Income towards Parent Company (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Income towards Parent Company of -$60.1 million for Q3 2025, down 48.7% on a YoY basis from -$117.2 million in Q3 2024, and down 15.13% sequentially from -$52.2 million in Q2 2025.
KalVista Pharmaceuticals (KALV) Income towards Parent Company (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Income towards Parent Company data on file, last reported at -$60.1 million in Q3 2025.
- For the quarter ending Q3 2025, Income towards Parent Company fell 48.7% year-over-year to -$60.1 million; the trailing twelve-month figure through Jul 2025 stood at -$164.4 million (down 107.85% YoY), and the FY2025 full-year result was -$183.5 million, down 248.36% from the prior year.
- Income towards Parent Company slipped to -$60.1 million in Q3 2025, from -$52.2 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $29.3 million in Q2 2024 to a low of -$60.1 million in Q3 2025.
- A 5-year average of -$33.8 million and a median of -$37.6 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 196.8% in 2024 and plunged 278.07% in 2025, its largest moves.
- Tracing KALV's Income towards Parent Company over 5 years: stood at -$33.3 million in 2021, then retreated by 11.62% to -$37.2 million in 2022, then fell by 4.7% to -$39.0 million in 2023, then plunged by 33.57% to -$52.1 million in 2024, then decreased by 15.52% to -$60.1 million in 2025.
- Business Quant data shows KALV's Income towards Parent Company at -$60.1 million in Q3 2025, -$52.2 million in Q2 2025, and -$52.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -60.14 Mn |
| Apr 30, 2025 | -52.23 Mn |
| Oct 31, 2024 | -52.06 Mn |
| Jul 31, 2024 | -40.44 Mn |
| Apr 30, 2024 | 29.33 Mn |
| Jan 31, 2024 | -29.03 Mn |
| Oct 31, 2023 | -38.98 Mn |
| Jul 31, 2023 | -38.84 Mn |
| Apr 30, 2023 | -30.30 Mn |
| Jan 31, 2023 | -37.40 Mn |
| Oct 31, 2022 | -37.23 Mn |
| Jul 31, 2022 | -38.11 Mn |
| Apr 30, 2022 | -57.36 Mn |
| Jan 31, 2022 | -37.86 Mn |
| Oct 31, 2021 | -33.35 Mn |
| Jul 31, 2021 | -22.09 Mn |
| Apr 30, 2021 | -19.37 Mn |
| Jan 31, 2021 | -13.05 Mn |
| Oct 31, 2020 | -13.28 Mn |
| Jul 31, 2020 | -14.78 Mn |